This Million Targets Drug: A $7M Bet on a CNS Breakthrough
A focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
Discover how to utilize your skills to generate extra cash. Unlock new income opportunities today.
20,528 articlesA focused look at a $7 million wager on a CNS drug maker in Phase 3. Learn what this move signals about biotech momen...
SVOL harvests the volatility risk premium by shorting VIX futures, paying a high dividend, yet a volatile market test...
Pfizer stock climbs as analysts weigh a pivotal prostate cancer trial. A Guggenheim bull case sees a $36 target by ye...
Barclays has boosted its Ionis target to $106, signaling a roughly 46% upside from recent levels as olezarsen eyes pe...
Markets grapple with a hypothetical energy shock after a White House remark suggesting oil could surge to $200 per ba...
Arm Holdings stunned markets with a powerful run, then pulled back after earnings. This guide breaks down whether thi...
This guide breaks down the dynatrace (dt) 2026 earnings narrative for investors. It covers growth drivers, margins, g...
A new AI-driven supercycle is unfolding, but you don’t need to chase dramatic bets. This guide explains how agentic A...
Microsoft posts solid Q3 results, showing AI and cloud momentum that investors say could unlock value in Big Tech. Th...
Apple hits a fresh 52-week high as Services revenue climbs and iPhone demand remains strong. The move fuels a buy, ho...
NVIDIA is more than a chip maker; it’s the AI backbone for modern computing. This guide explains why NVIDIA still art...
Meta unveils a groundbreaking $145 billion AI infrastructure plan for 2026, signaling a bold pivot from social media ...